Exclusive: ElectraCard admits system breached in global ATM heist

By Kaustubh Kulkarni MUMBAI (Reuters) - India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this ...

By Kaustubh Kulkarni and Suchitra Mohanty NEW DELHI/MUMBAI (Reuters) - The Supreme Court rejected Swiss drugmaker Novartis AG's (NOVN.VX: Quote, Profile, Research) plea for patent protection of its cancer drug Glivec, a move likely to boost the ...

Analysis: Big Pharma down, not out, after Indian patent blow 4:03pm BST By Ben Hirschler and Kaustubh Kulkarni LONDON/MUMBAI (Reuters) - Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but ...

File photo illustration of pills of all kinds, shapes and colours, March 2003. REUTERS/Jacky Naegelen/Files By Kaustubh Kulkarni MUMBAI (Reuters) - Global drugmakers, battered by recent intellectual property decisions in India, are girding for a ...

By Kaustubh Kulkarni MUMBAI (Reuters) - BDR Pharmaceuticals said on Monday it has applied to the patent office for a compulsory licence to sell a generic version of Bristol-Myers Squibb Co's (BMY.N: Quote, Profile, Research) cancer drug dasatinib, ...

NEW Former test bowler Shanthakumaran Sreesanth and two other players were arrested along with 11 bookmakers on Thursday on suspicion of spot-fixing in the Indian Premier League (IPL The case has prompted the Indian government to look at the ...

MUMBAI/BANGALORE Global banks that ship work to be processed in India, either in-house or to big IT services vendors, were already under pressure to step up oversight of back-office functions after a series of scandals last year. Last week, U.S.

MUMBAI, May 8 (Reuters) - Three months ended March 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 4.08 vs 1.56 Net Sales 25.37 vs 18.83 Results are consolidated. NOTE: Lupin Ltd is a drugmaker. (Reporting by ...

MUMBAI, May 8 (Reuters) - Ranbaxy Laboratories, India's largest drugmaker by sales, reported a 90 percent drop in first quarter net profit compared to the same year-ago period, when it had exclusive rights to a generic version of cholesterol ...